Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 24, 1999

View Archived Issues

GM-CSF and MDX-H210 assessed in pilot trial in cancer patients

Novartis R&D day 1999: Innovation drives future growth

KRN-8602 studied as new agent for recurrent high-grade glioma

Licensing opportunity from ASU: use of spongistatin 1 to treat fungal infections

Stylostatin 2 available for licensing from ASU

Novel karenitecin from BioNumerik inhibits Topo I and is synergistic with a TS inhibitor

Intranasal and i.p. administration of anti-IL-5 MAb equieffective in asthmatic mice

Dual PDE4/TNF-alpha inhibitors synthesized and tested at Suntory

Potent group II metabotropic glutamate receptor agonists in the Taisho pipeline

Kyowa Hakko presents heterocyclic compounds for osteoporosis

Complement inhibitor TP-10 enters infant trial for cardiopulmonary bypass

(R)-H-DOA: new agent for osteoporosis extracted from plants

Cantab reports positive phase I results for DISC HSV vaccine

Idun receives SBIR grant for apoptosis inhibitor research

First treatment for postherpetic neuralgia reaches U.S. market

Convenient new insulin mixture by Lilly offers better glycemic control

FDA requests additional clinical data for Avanir's docosanol cream

Teva completes merger of Copley

Cambridge Combinatorial announces name change and highlights success during first half

SB-269652 selectively antagonizes dopamine D3 receptors implicated in schizophrenia

rhIL-10 improves survival and attenuates myocardial damage in experimental viral myocarditis

Enrollment completed for phase IIb memantine trial in diabetic peripheral neuropathy

Patient enrollment complete in first of United Therapeutics' pulmonary hypertension trials

Citalopram exerts its in vitro and in vivo effects through the (S)-enantiomer

Fournier synthesizes novel potent B2 agonists resistant to enzymatic degradation

Acamprosate attenuates food craving in subjects with bulimia nervosa

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...